Figure 3.

Albumin administration shifts AD/ACLF plasma LM profiles and prealbumin LM profiles identifies 2 distinct AD/ACLF patient groups with a hyperactivated (group 2) and hypoactivated (group 1) LM phenotype. LM profiles interrogated using partial least square discriminant analysis. (A) 2D score plot with baseline and post treatment plasma LM profiles interrogated using principle component analysis. 2D score plot (top), 2D loading plot (bottom). (B) 2D loading plot with pre-treatment plasma pro-resolving and inflammation-initiating mediators identifies 2 distinct groups: group 1 (red) and group 2 (blue). (C) Assessment of lipid mediator profiles in each of these groups pre albumin treatment demonstrated a hypo-activated profile (Group 1) with reduced concentrations of several proresolving and inflammation initiating mediators. The second hyper-activated group was characterized by overall elevated lipid mediator concentrations (Group 2). Results mean ± standard error of the mean, representative of 10 patients.